ADH-1
(Synonyms: N-Ac-CHAVC-NH2) 目录号 : GC32922
A cyclic peptide antagonist of N-cadherin
Cas No.:229971-81-7
Sample solution is provided at 25 µL, 10mM.
ADH-1 is a cyclic peptide antagonist of N-cadherin. 1 It inhibits neurite outgrowth in cerebellar neurons cultured on N-cadherin-expressing 3T3 cell monolayers (IC50 = 0.323 mM). ADH-1 (0.2 mg/ml) inhibits cell scattering and motility induced by collagen I in Capan-1 cells and wild-type and N-cadherin-overexpressing BxPC-3 cells.2 It induces apoptosis in N-cadherin-overexpressing, but not knockdown, BxPC-3 cells when used at a concentration of 1 mg/ml. ADH-1 (50 mg/kg) reduces tumor growth in an N-cadherin-overexpressing BxPC-3 mouse xenograft model.
1.Williams, E., Williams, G., Gour, B.J., et al.A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motifJ. Biol. Chem.275(6)4007-4012(2000) 2.Shintani, Y., Fukumoto, Y., Chaika, N., et al.ADH-1 suppresses N-cadherin-dependent pancreatic cancer progressionInt. J. Cancer122(1)71-77(2008)
Animal experiment: | Animals are anesthetized, and 40 μL of a single cell suspension containing 50,000 cells is injected into the pancreas. Mice are randomized into treatment groups 10 days after surgery. For treatment, mice are injected intraperitoneally once per day with ADH-1 at 50 mg/kg in 100 μL PBS (×1 per day, ×5 per week for 4 weeks). For in vivo bioluminescence, D-Luciferin is administered by intraperitoneal injection. Data are acquired 20 min after injection using the IVIS system. Tumor growth is monitored every 10 days from day 10 to day 50 after surgery. Luciferase activity is quantified using the IVIS system. Two months after surgery, the mice are killed, and the pancreas, liver, lung, and disseminated nodules are harvested, fixed in 10% buffered formalin, and embedded in paraffin. Serial 5-μM sections are cut, mounted on slides, and stained with H&E using standard procedures. Sections are also stained for TUNEL. Sections are examined using a Zeiss Axioscop 40 microscope equipped with an AxioCam MR digital camera and software. |
References: [1]. Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. | |
| Cas No. | 229971-81-7 | SDF | |
| 别名 | N-Ac-CHAVC-NH2 | ||
| Canonical SMILES | O=C([C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC1=CN=CN1)N2)=O)=O)=O)CSSC[C@H](NC(C)=O)C2=O)N | ||
| 分子式 | C22H34N8O6S2 | 分子量 | 570.69 |
| 溶解度 | DMSO : 2.2 mg/mL (3.85 mM) | 储存条件 | Store at -20°C,unstable in solution, ready to use. |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7523 mL | 8.7613 mL | 17.5226 mL |
| 5 mM | 0.3505 mL | 1.7523 mL | 3.5045 mL |
| 10 mM | 0.1752 mL | 0.8761 mL | 1.7523 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet